Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

<h4>Background</h4>Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho, Delvys Rodriguez-Abreu, Ihab Abdulkader, Josep Ramirez, Noemí Reguart, Marta Salido, Lara Pijuán, Edurne Arriola, Julián Sanz, Victoria Folgueras, Noemí Villanueva, Javier Gómez-Román, Manuel Hidalgo, Fernando López-Ríos
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b8191
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Ejemplares similares